Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1981-2000 of 3,900 trials

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Stage III Lung Cancer: Surgery and Durvalumab Study

We are exploring whether surgery is safe for patients with initially unresectable stage III lung cancer after high-dose treatment. We also want to see if they can benefit from a follow-up therapy called durvalumab.

Stage III Non-Small Cell Lung CancerMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Enterococcus faecalis Endocarditis: Continuous Infusion Antibiotics Study

We are studying whether continuous infusion of ampicillin and ceftriaxone is as effective as standard treatment for patients with Enterococcus faecalis infective endocarditis. This may help improve treatment outcomes and reduce complications.

Enterococcal Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Semaglutide for Mood Improvement in Depression

We are studying if the medication semaglutide can help improve mood in people with major depressive disorder who are also overweight or obese. The trial will measure changes in depressive symptoms and overall well-being.

Unipolar DepressionObesity and Overweight6-12 monthsConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesCost ReimbursementPsychiatry

Lung Fibrosis: ENV-101 Treatment Study

We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Felzartamab for Late Antibody-Mediated Rejection

We are studying whether Felzartamab can help patients experiencing late antibody-mediated rejection after a transplant. This research aims to improve treatment options for these patients.

Late Antibody Mediated Renal Transplant Rejection>2 yearsEfficacy phase (II)Internal MedicineNephrology

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Fibrosis Assessment: 68Ga-FAPI Imaging Study

We are studying a new imaging technique to evaluate liver fibrosis in patients with suspected nonalcoholic steatohepatitis. This may help improve the accuracy of liver damage assessments compared to standard methods.

Non-Alcoholic Steatohepatitis (NASH)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyHepatologyInternal Medicine

Heart Attack Treatment: Timing of Medications

We are studying how the timing of beta blockers, ACE inhibitors, and SGLT2 inhibitors affects heart function in people who have had a heart attack. This may help us understand the best way to use these medications for better recovery.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced NSCLC: NVL-520 Treatment Study

We are testing a new medication, NVL-520, for patients with advanced ROS1-positive solid tumors, including non-small cell lung cancer. The study aims to find the best dose and evaluate its effectiveness and safety.

Advanced ROS1-positive Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Myeloma: Belantamab Mafodotin and Venetoclax Combination

We are testing a new combination treatment for patients with relapsed and refractory t(11;14) multiple myeloma. The goal is to see if this approach improves outcomes compared to current therapies.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Type 1 Diabetes: Study of NNC0363-1063

We are researching a new medicine to see how it affects healthy participants and those with type 1 diabetes. This study aims to gather information that could improve diabetes treatment.

Type 1 Diabetes1-2 yearsSafety phase (I)DiabetologyEndocrinology

Crohn's Disease: Stem Cell Treatment Study

We are exploring the use of fat-derived stem cells to treat fistulas in people with Crohn's disease. The goal is to find the best dose that may help improve healing.

Crohn’s Fistula1-2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyInternal Medicine

Fecal Microbiota Transplantation for Crohn’s Disease After Anti-TNF Withdrawal

We are studying whether fecal microbiota transplantation can help maintain remission in Crohn’s disease patients after stopping anti-TNF treatment. This trial compares FMT to a sham procedure to assess its effectiveness in preventing relapse and improving gut health.

Crohn's DiseaseConfirmation phase (III)Monitoring phase (IV)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Type 2 Diabetes: Dapansutrile Study

We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDiabetologyEndocrinology